Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; Association with pro-inflammatory cytokines

Chang Ki Min; Seok Lee; Yoo Jin Kim; Ki Seong Eom; Jong Wook Lee; Woo Sung Min; Chun Choo Kim; Chul Soo Cho; Gyeongsin Park

doi:10.1111/j.0902-4441.2005.t01-1-EJH2437.x

Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; Association with pro-inflammatory cytokines

Chang Ki Min
, Seok Lee
, Yoo Jin Kim
, Ki Seong Eom
, Jong Wook Lee
, Woo Sung Min
, Chun Choo Kim
, Chul Soo Cho
, Gyeongsin Park

Research output: Contribution to journal › Article › peer-review

50 Scopus citations

Abstract

The proteasome inhibitor, bortezomib, has anti-myeloma activity even in myeloma cells refractory to multiple prior treatments. Bortezomib blocks the production of nuclear factor-κB (NFκB)-mediated pro-inflammatory cytokines. We report a patient with myeloma who developed a cutaneous leucoclastic vasculitis (LV) after bortezomib treatment. The patient with LV exhibited a marked increase in serum levels of IL-6, TNF-α, and C-reactive protein (CRP). Bortezomib administration may enhance the release of pro-inflammatory cytokines, which might play a role in bortezomib-induced cutaneous LV.

Original language	English
Pages (from-to)	265-268
Number of pages	4
Journal	European Journal of Haematology
Volume	76
Issue number	3
DOIs	https://doi.org/10.1111/j.0902-4441.2005.t01-1-EJH2437.x
State	Published - Mar 2006

Keywords

Bortezomib
IL-6
Leucolcastic vasculitis
Multiple myeloma
TNF-α

Access to Document

10.1111/j.0902-4441.2005.t01-1-EJH2437.x

Cite this

@article{751803b39d9c4f9f98bfe2fbfcc7e839,

title = "Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; Association with pro-inflammatory cytokines",

abstract = "The proteasome inhibitor, bortezomib, has anti-myeloma activity even in myeloma cells refractory to multiple prior treatments. Bortezomib blocks the production of nuclear factor-κB (NFκB)-mediated pro-inflammatory cytokines. We report a patient with myeloma who developed a cutaneous leucoclastic vasculitis (LV) after bortezomib treatment. The patient with LV exhibited a marked increase in serum levels of IL-6, TNF-α, and C-reactive protein (CRP). Bortezomib administration may enhance the release of pro-inflammatory cytokines, which might play a role in bortezomib-induced cutaneous LV.",

keywords = "Bortezomib, IL-6, Leucolcastic vasculitis, Multiple myeloma, TNF-α",

author = "Min, \{Chang Ki\} and Seok Lee and Kim, \{Yoo Jin\} and Eom, \{Ki Seong\} and Lee, \{Jong Wook\} and Min, \{Woo Sung\} and Kim, \{Chun Choo\} and Cho, \{Chul Soo\} and Gyeongsin Park",

year = "2006",

month = mar,

doi = "10.1111/j.0902-4441.2005.t01-1-EJH2437.x",

language = "English",

volume = "76",

pages = "265--268",

journal = "European Journal of Haematology",

issn = "0902-4441",

publisher = "John Wiley and Sons Inc.",

number = "3",

}

TY - JOUR

T1 - Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; Association with pro-inflammatory cytokines

AU - Min, Chang Ki

AU - Lee, Seok

AU - Kim, Yoo Jin

AU - Eom, Ki Seong

AU - Lee, Jong Wook

AU - Min, Woo Sung

AU - Kim, Chun Choo

AU - Cho, Chul Soo

AU - Park, Gyeongsin

PY - 2006/3

Y1 - 2006/3

N2 - The proteasome inhibitor, bortezomib, has anti-myeloma activity even in myeloma cells refractory to multiple prior treatments. Bortezomib blocks the production of nuclear factor-κB (NFκB)-mediated pro-inflammatory cytokines. We report a patient with myeloma who developed a cutaneous leucoclastic vasculitis (LV) after bortezomib treatment. The patient with LV exhibited a marked increase in serum levels of IL-6, TNF-α, and C-reactive protein (CRP). Bortezomib administration may enhance the release of pro-inflammatory cytokines, which might play a role in bortezomib-induced cutaneous LV.

AB - The proteasome inhibitor, bortezomib, has anti-myeloma activity even in myeloma cells refractory to multiple prior treatments. Bortezomib blocks the production of nuclear factor-κB (NFκB)-mediated pro-inflammatory cytokines. We report a patient with myeloma who developed a cutaneous leucoclastic vasculitis (LV) after bortezomib treatment. The patient with LV exhibited a marked increase in serum levels of IL-6, TNF-α, and C-reactive protein (CRP). Bortezomib administration may enhance the release of pro-inflammatory cytokines, which might play a role in bortezomib-induced cutaneous LV.

KW - Bortezomib

KW - IL-6

KW - Leucolcastic vasculitis

KW - Multiple myeloma

KW - TNF-α

UR - https://www.scopus.com/pages/publications/33645071066

U2 - 10.1111/j.0902-4441.2005.t01-1-EJH2437.x

DO - 10.1111/j.0902-4441.2005.t01-1-EJH2437.x

M3 - Article

C2 - 16451401

AN - SCOPUS:33645071066

SN - 0902-4441

VL - 76

SP - 265

EP - 268

JO - European Journal of Haematology

JF - European Journal of Haematology

IS - 3

ER -

Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; Association with pro-inflammatory cytokines

Abstract

Keywords

Access to Document

Fingerprint

Cite this